Hyperphosphatemia Secondary to the Selective Fibroblast Growth Factor Receptor 1–3 Inhibitor Infigratinib (BGJ398) Is Associated with Antitumor Efficacy in Fibroblast Growth Factor Receptor 3–altered Advanced/Metastatic Urothelial Carcinoma

Publication | Open Access

DOI Full Paper Access

Citations

References

2020

Year

Yung Lyou, Petros Grivas, Jonathan E. Rosenberg, Jean Hoffman‐Censits, David I. Quinn, Daniel P. Petrylak, Matthew D. Galsky, Ulka N. Vaishampayan, Ugo De Giorgi, Sumati Gupta,

European Urology

UrologyHyperphosphatemia SecondaryGenitourinary CancerAdvanced/metastatic Urothelial CarcinomaCancer GrowthCancer Cell BiologyFibroblast Growth FactorMolecular OncologyMedicineRadiation OncologyCancer ResearchInhibitor Infigratinib